Fatih Ozaltin

Prof. Dr. Fatih Ozaltin

orcid

Research Focus & Metrics

Academic Career Length

24Years (2003-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 March 2013 in Journal of the American Society of Nephrology
Verified
Journal Article
Open access
PDF file
FOFatih Ozaltin
Fatih Ozaltin
BLBinghua Li
Binghua Li
ARAlysha Rauhauser
Alysha Rauhauser
SASung-Wan An
Sung-Wan An
OSOguz Soylemezoglu
Oguz Soylemezoglu
MAMassimo Attanasio
Massimo Attanasio
Renal microangiopathies and membranoproliferative GN (MPGN) can manifest similar clinical presentations and histology, suggesting the possibility of a common underlying mechanism in some cases. Here, we performed homozygosity mapping and whole exome sequencing in a Turkish consanguineous family and identified DGKE gene variants as the cause of a membranoproliferative-like glomerular microangiopathy. Furthermore, we identified two additional DGKE variants in a cohort of 142 unrelated patients diagnosed with membranoproliferative GN. This gene encodes the diacylglycerol kinase DGKε, which is an intracellular lipid kinase that phosphorylates diacylglycerol to phosphatidic acid. Immunofluorescence confocal microscopy demonstrated that mouse and rat Dgkε colocalizes with the podocyte marker WT1 but not with the endothelial marker CD31. Patch-clamp experiments in human embryonic kidney (HEK293) cells showed that DGKε variants affect the intracellular concentration of diacylglycerol. Taken together, these results not only identify a genetic cause of a glomerular microangiopathy but also suggest that the phosphatidylinositol cycle, which requires DGKE, is critical to the normal function of podocytes.

1 July 2011 in The American Journal of Human Genetics
Verified
Journal Article
Closed access
FOFatih Ozaltin
Fatih Ozaltin
TITulin Ibsirlioglu
Tulin Ibsirlioglu
ETEkim Z. Taskiran
Ekim Z. Taskiran
DBDilek Ertoy Baydar
Dilek Ertoy Baydar
FKFigen Kaymaz
Figen Kaymaz
ABAyşin Bakkaloglu
Ayşin Bakkaloglu

29 January 2021 in Nature Reviews Nephrology
Verified
Journal Article
Open access
PDF file
OBOlivia Boyer
Olivia Boyer
FSFranz Schaefer
Franz Schaefer
DHDieter Haffner
Dieter Haffner
DBDetlef Bockenhauer
Detlef Bockenhauer
THTuula Hölttä
Tuula Hölttä
MVMarina Vivarelli
Marina Vivarelli
Congenital nephrotic syndrome (CNS) is a heterogeneous group of disorders characterized by nephrotic-range proteinuria, hypoalbuminaemia and oedema, which manifest in utero or during the first 3 months of life. The main cause of CNS is genetic defects in podocytes; however, it can also be caused, in rare cases, by congenital infections or maternal allo-immune disease. Management of CNS is very challenging because patients are prone to severe complications, such as haemodynamic compromise, infections, thromboses, impaired growth and kidney failure. In this consensus statement, experts from the European Reference Network for Kidney Diseases (ERKNet) and the European Society for Paediatric Nephrology (ESPN) summarize the current evidence and present recommendations for the management of CNS, including the use of renin–angiotensin system inhibitors, diuretics, anticoagulation and infection prophylaxis. Therapeutic management should be adapted to the clinical severity of the condition with the aim of maintaining intravascular euvolaemia and adequate nutrition, while preventing complications and preserving central and peripheral vessels. We do not recommend performing routine early nephrectomies but suggest that they are considered in patients with severe complications despite optimal conservative treatment, and before transplantation in patients with persisting nephrotic syndrome and/or a WT1-dominant pathogenic variant.

1 January 2016 in Journal of the American Society of Nephrology
Verified
Journal Article
Open access
PDF file
EKEmine Korkmaz
Emine Korkmaz
BLBeata S. Lipska-Ziętkiewicz
Beata S. Lipska-Ziętkiewicz
OBOlivia Boyer
Olivia Boyer
OGOlivier Gribouval
Olivier Gribouval
CFCecile Fourrage
Cecile Fourrage
FSFranz Schaefer
Franz Schaefer
Hereditary defects of coenzyme Q10 biosynthesis cause steroid-resistant nephrotic syndrome (SRNS) as part of multiorgan involvement but may also contribute to isolated SRNS. Here, we report 26 patients from 12 families with recessive mutations in ADCK4. Mutation detection rate was 1.9% among 534 consecutively screened cases. Patients with ADCK4 mutations showed a largely renal-limited phenotype, with three subjects exhibiting occasional seizures, one subject exhibiting mild mental retardation, and one subject exhibiting retinitis pigmentosa. ADCK4 nephropathy presented during adolescence (median age, 14.1 years) with nephrotic-range proteinuria in 44% of patients and advanced CKD in 46% of patients at time of diagnosis. Renal biopsy specimens uniformly showed FSGS. Whereas 47% and 36% of patients with mutations in WT1 and NPHS2, respectively, progressed to ESRD before 10 years of age, ESRD occurred almost exclusively in the second decade of life in ADCK4 nephropathy. However, CKD progressed much faster during adolescence in ADCK4 than in WT1 and NPHS2 nephropathy, resulting in similar cumulative ESRD rates (>85% for each disorder) in the third decade of life. In conclusion, ADCK4-related glomerulopathy is an important novel differential diagnosis in adolescents with SRNS/FSGS and/or CKD of unknown origin.

24 May 2008 in Rheumatology International
Verified
Journal Article
Closed access
PDF file
YBYelda Bilginer
Yelda Bilginer
FOFatih Ozaltin
Fatih Ozaltin
CBCeyla Basaran
Ceyla Basaran
ADAli Duzova
Ali Duzova
NBNesrin Besbas
Nesrin Besbas
ABAysin Bakkaloglu
Aysin Bakkaloglu

24 March 2017 in Pediatric Nephrology
Verified
Journal Article
Closed access
PDF file
MAMustafa Atmaca
Mustafa Atmaca
BGBora Gulhan
Bora Gulhan
EKEmine Korkmaz
Emine Korkmaz
MIMihriban Inozu
Mihriban Inozu
OSOguz Soylemezoglu
Oguz Soylemezoglu
FOFatih Ozaltin
Fatih Ozaltin